Advertisement

Topics

Novan Therapeutics Company Profile

06:57 EDT 19th June 2018 | BioPortfolio


News Articles [786 Associated News Articles listed on BioPortfolio]

Novan Makes Kelly Martin’s CEO Role Permanent

Kelly Martin has been named permanent CEO of Novan (NASDAQ: NOVN). The Morrisville, NC-based drug developer appointed Martin interim CEO last June, part of a corporate shakeup in which the company lai...

Novan nets $35.6mm in FOPO

Novan Inc. (nitric oxide (NO) drug delivery) netted $35.6mm in a follow-on public offering of 10mm common shares and accompanying four-year warrants (to purchase up to 10mm additional common shares at...

The Klein Law Firm Reminds Investors of a Class Action on Behalf of Novan, Inc. Shareholders and a Lead Plaintiff Deadline of January 2, 2018 (NOVN)

NEW YORK, NY / ACCESSWIRE / December 21, 2017 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Novan, Inc. (NASDAQ: NOVN) who purchased share...

Novan raises $38M follow-on

Novan to Participate in Upcoming Investor Conferences

MORRISVILLE, N.C., June 13, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that members of management are scheduled to attend the 2018 Cantor Dermatol...

Dr. Eugene Sun Appointed to Novan Board of Directors

Complements existing Board expertise as 30-year clinician, drug developer and former biopharmaceutical CEOWill provide expert perspective on the clinical application of the underlying nitric oxide ...

Novan Advances Organization and Strengthens Leadership Team

CEO Role No Longer “Interim”Clinical Operations Role Established Finance Team Positioned for the Future MORRISVILLE, N.C., April 12, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" ...

Novan Announces Closing of Offering of Common Stock and Warrants

MORRISVILLE, N.C., Jan. 11, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced that it has closed its previously announced underwritten public offerin...

PubMed Articles [411 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Eyes on New Product Development: Preclinical Research.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [144 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1236 Associated Companies listed on BioPortfolio]

Novan Therapeutics

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Novan Therapeutics" on BioPortfolio

We have published hundreds of Novan Therapeutics news stories on BioPortfolio along with dozens of Novan Therapeutics Clinical Trials and PubMed Articles about Novan Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Novan Therapeutics Companies in our database. You can also find out about relevant Novan Therapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record